California Institute of Technology

Pasadena, California
John G. Kirkwood and Arthur A. Noyes Professor in the Division of Chemistry and Chemical Engineering


Many cancers arise as a result of damage to DNA that persists and changes the functioning of the cell. Some cancers are associated with a deficiency in the ability of the cell to find and repair such damage. Dr. Jacqueline Barton’s research seeks to understand fundamentally how this damage arises, how regions of the genome may be protected from such damage, and how such damage is found and repaired.

Dr. Barton’s explored biological roles for oxidative damage to DNA in the context of DNA damage and repair. In one important study, she explored how oxidative stress affects the ability of tumor suppressor protein, p53, to bind to different DNA segments that it controls to turn on or off other genes. The protein p53, is considered the “guardian” of the cell and mutations in p53 are well known to be associated with cancer. These results point to a role for DNA-oxidative stress mediated charge transport as a first signal for oxidative stress directing p53 to different promoters depending upon cellular stresses.

Her lab has increased our understanding of how DNA damage may activate a wide range of signals within the cell and how that damage is detected and repaired. Remarkably, her results demonstrated that it appears that DNA-mediated charge transport, can be the first step in activating either cell death or DNA repair. Her data allow a much clearer understanding of the first molecular steps in cancerous transformation and likely also provide a path to early cancer diagnosis.


Dr. Jacqueline K. Barton received her B.A. from Barnard College and her Ph.D. in Inorganic Chemistry at Columbia University. She then conducted postdoctoral work at Bell Laboratories and Yale University. Dr. Barton held professorships at Hunter College, City University of New York and Columbia University.

Dr. Barton joined the faculty at Caltech in 1989. From 1997 to 2016 she held the Arthur and Marion Hanisch Memorial Professorship. From 2009 to 2019 she served as the Norman Davidson Leadership Chair.   She is the John G. Kirkwood and Arthur A. Noyes Professor in the Division of Chemistry and Chemical Engineering. Through this research, Barton has trained more than 100 graduate students and postdoctoral students, with about half in academic positions.

Dr. Barton has received numerous awards including:  the Alan T. Waterman Award of the National Science Foundation, the Weizmann Women & Science Award, the ACS Gibbs Medal, and the National Academy of Sciences Award in Chemical Science to name a few. She was a fellow of the Sloan Foundation, a Dreyfus Teacher-Scholar, and an NSF Presidential Young Investigator.

She is a recipient of a prestigious MacArthur Foundation Fellowship and she is a member of the American Academy of Arts and Sciences, the American Philosophical Society, the National Academy of Sciences and the National Academy of Medicine, along with an honorary fellowship in the Royal Society of Chemistry. She has also served the chemical community through her participation in ACS, government and industrial boards. In October 2011, Dr. Barton received the 2010 National Medal of Science from President Obama.

Areas of Focus

Cancer Types

Years of NFCR Funding


Related Content

Research Highlight: Preventing Breast Cancer Brain Metastasis

National Foundation for Cancer Research funded researcher Dr. Daniel A Haber recently unearthed an exciting discovery that may add years to the lives of late-stage breast cancer patients. Dr. Haber is fascinated by understanding drug resistance on a deeper level by studying individual tumor cells in patients’ blood. In December 2020, Dr. Haber and his team shared their exciting findings on how brain metastasis, or the spread of cancer to the brain, may be prevented. Brain metastases occur in about 10% of all patients with cancer and in as many as a third of women with advanced metastatic breast cancer. Though experts have made great strides in suppressing the spread of cancer, there is still little known about the cellular pathways that enable cancer cells to selectively grow in the brain; that is, until Dr. Haber and his research team identified a signaling pathway which appeared significantly more active in brain metastases from breast cancer. “We were looking for what properties of some breast cancer cells made it possible for the cells to grow in the brain, which is a rare but often deadly complication of breast cancer,” Dr. Haber explained. “We weren’t sure what we would find. In a way that’s what makes the discovery process so exciting.” The research commenced approximately 10 years ago while investigating circulating tumor cells (CTCs). As their research progressed, the team homed in on a specific signaling pathway named HIF1A. Using cells from women with breast cancer, the team observed how these cells acted in animal models. It was discovered that if HIF1A was suppressed, the rate of proliferation (or rapid growth) was reduced. Simply put, blocking the HIF1A signaling pathway could reduce the rate of brain metastasis or even prevent it all together. “HIF1A is not specific to brain metastasis, since it’s a very broadly activated pathway in many cancers,” Dr. Haber began. “However, it appears to be more active in brain metastases from breast cancer than in primary breast cancers, and that may help explain what makes these metastases to the brain so unique and so difficult to treat.” The pathway identified in this research is already well known in the cancer world, however its special relevance to the brain was not known until now. Theoretically, a drug could be developed to suppress HIF1A and, in turn, prevent the spread of cancer. While a very promising discovery, Dr. Haber explains that there is far more work to be done. “There are a few HIF1A suppressing drugs now being tested in clinical trials for other indications,” Dr. Haber said, “However, we would have to expand this to multiple different models and systems before we could contemplate an intervention.” In regard to the length of time it takes to have a discovery such as this transitioned to mainstream treatment, Dr. Haber explains that it “depends on the discovery, its potential applications and some ‘luck’.” While the process from discovery to clinical treatment is getting faster all the time, it is likely going to take five to ten years before this finding is implemented into treatment. As for Dr. Haber, he has already planned plenty of work […]

Genetic Testing: Learning More About Your Cancer Risk

Genetic testing can be an important tool in helping patients learn about their inherited cancer risk, but the results are not always as clear as patients might expect. Just as traits such as hair color and eye color can be passed down from parents to their children, so too can the risk for developing certain types of cancer. Scientists know that certain inherited gene mutations — small changes in a person’s DNA — can increase a person’s risk for developing diseases such as breast cancer, ovarian cancer, and colon cancer. Genetic testing examines a person’s DNA to determine if such mutations are present, helping patients better understand their cancer risk and, in some cases, allowing them to take charge of their health before receiving a devastating diagnosis. Understanding the Basics of Genetic Testing Only five to 10 percent of all cancers are believed to be tied to an inherited gene mutation.1 Genetic testing can help determine whether an individual has inherited a specific gene mutation (or mutations) that put him or her at higher risk for developing certain cancers. Most genetic tests require a small blood sample from the patient, but some tests can be performed using urine, saliva, or a cheek swab. The sample is sent to a special laboratory and results are usually provided to the patient’s doctor or genetic counselor within several weeks.2 Genetic testing can return one or a combination of the following results: Positive: The laboratory identified a genetic mutation that is associated with an inherited cancer risk.2 Negative: The laboratory did not find the specific genetic mutation (or mutations) that the test was designed to detect.2 Inconclusive: The laboratory was not able to determine whether a specific genetic mutation (or mutations) was present in the sample provided.2 Variance of Uncertain Significance: The laboratory identified a genetic mutation that has not been previously associated with cancer.2 No test can provide exact answers about a person’s inherited cancer risk. Genetic testing can tell you whether a specific genetic mutation is present in your DNA, but it cannot tell you for certain that you will develop the disease associated with that mutation later in life.3 Knowing Your Cancer Risk: Is Genetic Testing Right for You? Doctors often only recommend genetic testing for patients whose families have a history of certain cancers or patterns of cancer. According to the American Cancer Society, people who meet the following criteria might consider genetic testing: Cancer diagnoses in multiple first-degree relatives, including parents, siblings, or children1 Numerous relatives on one side of the family who have been diagnosed with the same cancer1 Family history of cancers linked to a single gene mutation, such as breast cancer, ovarian cancer, or pancreatic cancer1 Family member(s) who has been diagnosed with more than one type of cancer1 Family member(s) who has been diagnosed with cancer at a younger age than typically seen for that cancer, such as colon cancer1 Close relatives who have been diagnosed with cancers linked to rare hereditary cancer syndromes, such as Hereditary Breast & Ovarian Cancer Syndrome (HBOC), Cowden Syndrome, or Lynch Syndrome1 Family member(s) who has been diagnosed with […]

Sarcoma: The Young Person’s Cancer?